ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) sits in the top decile of US sponsors by registered trial count (#583 of 15,742 sponsors by registered trial count).
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA): 27 sponsored US clinical trials, none currently recruiting.
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) sponsors 27 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 22 completed. 0 of these trials are in Phase 3-4 (later-stage) and 26 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cancer, with 2 trials.
Top-decile sponsor footprint
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) ranks in the top decile of sponsors by registered trial count (#583 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
22 of 26 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
27 total, page 1 of 1
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
NCT03162536
Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002)
NCT03094832
Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)
NCT02761694
Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples
NCT02762721
Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
NCT02476955
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
NCT01473095
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT01395758
Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations
NCT01225536
Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy
NCT00988741
Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors
NCT00827177
Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
NCT00825487
Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors
NCT00874042
Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)
NCT00802555
A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT00777309
Bioequivalence Study of ARQ 197 Amorphous and Crystalline Polymorphs A and B in Normal Healthy Volunteers
NCT00658554
A Study of ARQ 197 in Healthy Volunteers to Assess the Pharmacokinetic (PK) Profile in Extensive and Poor Metabolizers as Defined by Cytochrome P450 2C19 (CYP 2C19) Genotype
NCT00651638
A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors
NCT00612703
Phase 2 Study in Patients With MiT Tumors
NCT00557609
An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors
NCT00524524
An Extension Study for Patients Previously Treated With ARQ 501
NCT00622063
A Study of ARQ 171 in Patients With Advanced Solid Tumors
NCT00398840
A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck
NCT00358930
Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma
NCT00310518
ARQ 197 in Subjects With Metastatic Solid Tumors
NCT00302172
ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer
NCT00102700
ARQ 501 in Combination With Docetaxel in Patients With Cancer
NCT00099190
ARQ 501 in Subjects With Cancer
NCT00075933
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 19 |
| Phase 2 | 7 |
How the ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) early-phase archive is shaped
27 indexed studies, none listed as recruiting (0% open); 22 completed (81%).
Phase mix: 0 late (III/IV) vs 26 early (I/II) (early-phase heavy).
Top condition: Cancer (2 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA): archived-pipeline peers nationwide
Peers matched on 27 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 27 archived trials
- Akron Children's Hospital · 27 trials · 7% recruiting
- AVEO Pharmaceuticals · 27 trials · 7% recruiting
- Dompé Farmaceutici S.p.A · 27 trials · 15% recruiting
- Florida Atlantic University · 27 trials · 19% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) page
27 registered trials is a research-attention snapshot, not an endorsement of ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) or any single study.
- None of ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Cancer is the condition ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) pipeline card: 27 registered trials from official public datasets.Report a data error.